Multicentric Castleman disease revealing complete signal transducer and activator of transcription 1 deficiency treated by JAK1/2 inhibition
- 2 July 2021
- journal article
- letter
- Published by Elsevier BV in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (10), 3838-3840.e1
- https://doi.org/10.1016/j.jaip.2021.06.031
Abstract
No abstract availableKeywords
Funding Information
- Chung Hua University
This publication has 9 references indexed in Scilit:
- Successful management of familial hemophagocytic lymphohistiocytosis by the JAK 1/2 inhibitor ruxolitinibPediatric Blood & Cancer, 2021
- A Novel Complete Autosomal-Recessive STAT1 LOF Variant Causes Immunodeficiency with Hemophagocytic Lymphohistiocytosis–Like HyperinflammationThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1Oncogene, 2020
- Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two‐site retrospective cohort studyPediatric Blood & Cancer, 2019
- How i treat primary haemophagocytic lymphohistiocytosisBritish Journal of Haematology, 2018
- Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndromeBlood, 2016
- STAT1 deficiency redirects IFN signalling toward suppression of TLR response through a feedback activation of STAT3Scientific Reports, 2015
- Immunomodulatory functions of type I interferonsNature Reviews Immunology, 2012
- Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiencyNature Genetics, 2003